Arzneimittelforschung 2012; 62(01): 9-13
DOI: 10.1055/s-0031-1291361
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Bioequivalence Evaluation of Cefdinir in Healthy Fasting Subjects

Authors

  • J. Chen

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • B. Jiang

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • H. Lou

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • L. Yu

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
  • Z. Ruan

    1   Division of Clinical of Pharmacology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P. R. China
Weitere Informationen

Publikationsverlauf

received 15. September 2011

accepted 17. Oktober 2011

Publikationsdatum:
10. Januar 2012 (online)

Preview

Abstract

A simple and sensitive HPLC method was developed to determine cefdinir (CAS 91832-40-5) in human plasma. The method was validated by investigating the accuracy and precision for intra- and inter-day runs in a linear concentration from 0.05–2.0 µg/ml. The object of this study was to compare the bioavailability of cefdinir capsule (reference) and cefdinir granule (test) containing 100 mg of cefdinir. A randomized, open-label, single-dose, 2-way crossover bioequivalence study in 20 healthy, Chinese, male subjects was conducted. A 1-week wash-out period was applied. Blood samples were collected before and with 10 h after drug administration. The formulations were compared using the following pharmacokinetic parameters: AUC0-t, AUC0-∞ and C max. The 90% confidence interval (CI) of the ratios of log-transformed AUC0-t and AUC0-∞ were used to assess bioequivalence between the 2 formulations using the equivalence interval of 80 and 125%. The results showed that the 90% CI of the ratios of AUC0-t, AUC0-∞ and C max were 102.5% (94.7–111.0%), 103.4% (94.8–112.7%) and 106.4% (97.0–116.7%), respectively, which indicated 2 formulations of cefidinir are bioequivalent. Both treatments showed similar tolerability and safety.